CureVac’s Collaboration with GSK

Baker McKenzie advised CureVac on the deal. CureVac N.V., a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), restructured its existing collaboration...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

CureVac’s Collaboration with MD Anderson

Baker McKenzie advised CureVac N.V. on the deal. CureVac N.V., a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), entered into a...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Tubulis GmbH’s Series B2 Financing

Baker McKenzie advised EQT Life Sciences on the deal. EQT Life Sciences successfully closed a EUR 128 million (USD 138.8 million) Series B2 financing of Tubulis GmbH....

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

CTS Corporation’s Acquisition of Maglab AG

Baker McKenzie advised CTS Corporation on the deal. CTS Corporation executed the acquisition of Swiss-based maglab AG, a company with expertise in magnetic system design, primarily focused on...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Datwyler’s Acquisition of CTsystems AG

Baker McKenzie Switzerland advised Datwyler on the transaction. Wenger Vieli advised the shareholders of CTsystems. Datwyler executed the acquisition of Swiss startup company CTsystems AG. Datwyler...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here